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DrMichael Mulligan (Seattle, Wash). I would like to thank the
association for inviting me to discuss this paper and Dr Khan and
his colleagues for sending me the manuscript in advance. Congrat-
ulations on a fine presentation and for conducting a prospective ran-
domized trial in an attempt to answer a timely question. You added
50%more patients between submission of the abstract and the man-
uscript, so I paid attention and I think I understand your take-home
message but let’s work through this.
I have 2 comments and then 3 questions.
The first comment is that you combined heart and lung transplant
patients and I do not think that is appropriate. That is apples and or-
anges, and I think you think so, too, because you use different en-
trance criteria to include heart or lung transplant recipients.
Whereas pulmonary artery pressures and elevations in pulmonary
vascular resistance have obvious implications for outcomes in heart
transplant patients with right ventricular dysfunction, elevated pul-
monary artery pressures are not even used in the grading criteria for
primary graft dysfunction after lung transplantation. Rather, we use
P to F ratios and infiltrates.
Second comment—you raised 3 concerns about inhaled nitric
oxide: the need for complex delivery systems, potential toxicities,
and cost. Yet in your data and in your discussion, you realize that
both inhaled nitric oxide and nebulized prostacyclin require some-
what complex delivery systems and you observed no toxicity so it
really comes down to cost. If we have already spent so much, on
a lung transplantation for example, I think it is best to use the
best drug with the best bioavailability in the alveolar space with
the best effect on ventilation perfusion matching, accepting an in-
crease in cost that is real but only a small fraction of the overall
price of the successful patient outcome. Ultimately, we still do
not appear to know which agent is best.
I will move on to the questions.
First question, there were 17 patients in the abstract and 25 pa-
tients in the manuscript. The numbers are really too small to
draw any definitive conclusions about efficacy in heart transplant
recipients or in lung transplant recipients. Was this your target or
did you stop enrollment early for some reason?
Dr Khan. We initially had a target of 100 patients. However,
when we did our preliminary analysis and reviewed this with
______ we found reasonable data that we concluded the study
early.
DrMulligan. I would challenge the fact that you hit a home run
because hypoxia is—this is my second question. Hypoxia is the un-1424 The Journal of Thoracic and Cardiovascular Surdoing of a lung transplant recipient in primary graft dysfunction;
yet, in your manuscript you showed no improvement in P to F ratios
with either nebulized prostacyclin or inhaled nitric oxide. Many
other studies have shown beneficial effects with both. This is espe-
cially true with inhaled nitric oxide, presumably related to the better
alveolar distribution of a gas as compared with a nebulized solu-
tion. Why do you suppose that in your study you did not see any
improvement in P to F ratios? Did it have something to do with
the 8 additional patients added, because in your abstract you did
see a benefit, or was it because you simply did not have enough
acute graft dysfunction in lung transplant population?
DrKhan. The difference between the data in the abstract and the
manuscript with the larger numbers, the small difference in im-
provement in PF ratio became no longer significant. That was be-
cause in the group of patients that had a PF ratio of less than 200,
when you looked at that subgroup, they had approximately 50% in-
crease in PF ratio because their PF ratio started in the 50–100 range.
However, when you look at the mean of the whole group, the aver-
age is 200–250.When we did look at that group separately, they did
have an improvement in oxygenation from both agents. However,
when we added more patients, none of whom had hypoxia, it di-
luted out that finding.
DrMulligan. I think that gets back to the original comment that
we probably should not mix heart and lung transplant patients to-
gether in such a study and we should expand it to include more
lung transplant patients.
The last question is that in your manuscript and in your presen-
tation you talked about a 5.3% incidence of grade III primary graft
dysfunction in your lung recipients, yet 5 of 17 or 5 of 25 had P to
F ratios of less than 200, which would imply a grade III primary
graft dysfunction if they were lung transplant recipients. What
was your actual incidence of primary graft dysfunction in this
population?
Dr Khan. It was 5.3% at 48 hours. However, that initial data of
the 5 patients who had hypoxemia initially was at the time of
randomization in the operating room, so several of these patients
improved during the next 48 hours such that there was only 1
patient remaining who met the criteria.
DrMulligan. There is an upfront and then there is a delayed as-
sessment, so I do not know which one is valid but it appeared to be
disparate between your early and late assessments.
Again congratulations and I appreciate the opportunity to dis-
cuss the paper.
Dr Khan. Thank you.gery c December 2009
